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or previous use of inhaled anticholinergics was not associated with a significant 
increased risk of AACG (active use: adjusted OR 1.32, 95% CI 0.83-2.10; non-active 
use: adjusted OR 1.13, 95% CI 0.72-1.75) compared to non-use, adjusting for use of 
other medications related to AACG. ConClusions: A relationship between the use 
of inhaled anticholinergics and the risk of AACG was not observed in this COPD pop-
ulation. However, the findings are limited due to the small sample size of the events.
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objeCtives: Chronic idiopathic/spontaneous urticaria (CIU) is a skin condition 
characterized by the presence of hives and angioedema lasting ≥ 6 weeks with no 
known cause. There is no specific ICD-9 code for CIU. This study aims to validate 
an ICD-9 based algorithm to identify patients with CIU to allow for epidemiologic 
research using administrative claims databases. Methods: Retrospective review 
of medical and billing records in 4 geographically-dispersed US allergy practices. 
Patients were eligible for inclusion if they met the either of these criteria: 1) ≥ 2 out-
patient visits with a diagnosis of idiopathic urticaria (ICD-9 708.1), other specified 
urticaria (708.8), or unspecified urticaria (708.9) ≥ 6 weeks apart, OR 2) ≥ 1 outpatient 
diagnosis of 708.1, 708.8 or 708.9 and 1 diagnosis of angioedema (995.1) ≥ 6 weeks 
apart. A random sample of patients known to have CIU were also included. Chart 
review was performed to collect information on ICD-9 codes, prescription medica-
tions, and clinical urticarial diagnoses abstracted from records of a random sample 
of eligible patients. Sensitivity and positive predictive value (PPV) were calculated. 
The study received central IRB approval. Results: There were 149 patients with a 
mean age of 41.1 years (SD: 20.8), 73.8% were female and 69.1% were white. For 104 
“true positive” patients, the mean (median) duration of CIU was 3.1(2.5) years. The 
claims algorithm had sensitivity of 71.1% and PPV of 90.4%. Using just the first algo-
rithm reduced PPV to 90.3% and sensitivity to 67.8%. Physicians most often identified 
CIU using the codes for idiopathic urticaria, unspecified urticaria and other urticarial 
conditions. ConClusions: PPV of 90.4% suggests patients identified using the 
tested ICD-9 algorithm are highly likely to have CIU. Sensitivity of 71.1% suggests 
that some patients with CIU would not be identified. Changes to the algorithm that 
increase sensitivity without decreasing PPV should be explored in future studies.
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objeCtives: Vitreomacular adhesion (VMA) can lead to pathologic traction and 
macular hole formation. In two phase 3 trials ocriplasmin induced a significant ana-
tomical response, as well as a significant functional response. The purpose of this 
analysis was to assess how the anatomic and visual function responses related to 
each other. Methods: An anatomic response was defined as complete non-surgical 
resolution of vitreomacular adhesion (VMA). Visual functional response was defined 
as either: non-surgical visual acuity improvement of ≥ 2 lines; or clinically mean-
ingful improvement in the visual function questionnaire (VFQ-25) composite score 
(> 3.6 points) or driving subscale (> 19.1 points). We defined complete responders 
as participants who improved both anatomically and functionally. Visual-function-
only responders, or anatomic-only-responders, were participants who improved 
in either category (but not both), and non-responders were participants without 
improvement in either category. We investigated the ocriplasmin effect for each 
of these response categories using generalized logit regression models with the 
non-responder group as baseline category. Results: The proportion of complete 
responders in the ocriplasmin group was 18.3%, versus 5.2% in the placebo group 
(p= 0.003). The proportion of visual-function-only responders was 36.8% and 29.0% 
(p= 0.0007); and the proportion of anatomic-only-responders was 10.2% and 5.2%, 
for ocriplasmin and placebo groups respectively (p< 0.0001). Ocriplasmin treatment 
produced a visual function response, either alone or in combination with an ana-
tomic response, in 55.1% of patients, compared to 34.2% of patients receiving pla-
cebo. ConClusions: The reason why visual function was larger than the anatomic 
response in the ocriplasmin treated group is not known, but the possibility of partial 
release of VMA positively affecting visual function warrants further investigation.
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objeCtives: Choroidal neovascularization (CNV) is the most common vision-
threatening complication associated with pathologic myopia (PM), or myopic CNV 
(mCNV). There is a lack of information on the epidemiology related to mCNV in 
the world and more so in Canada. This study aimed to determine the epidemi-
ology and the demographic and treatment characteristics of Canadian mCNV 
patients. Methods: Records from a longitudinal population-based database of 
more than 320,000 patients, collected from 75 physicians in Southwestern Ontario, 
Canada were analyzed between January 1, 2006 and December 31, 2011. Patient 
records were limited to subjects aged 18 years and older, and patients with at least 
one year of follow up. The clinical and demographics characteristics, medications, 
and resource use were reported in this study. A nested case-control study based on 
the final diagnosis of CNV secondary to PM was constructed within a PM cohort. In 
according to culture sensitivity reports is one of the rational utilization practices 
and one of the most important steps for combating multi drug resistance issue.
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PerSiStent otitiS media among texaS medicaid children – PreValence 
and health care utilization and coStS
Richards K.M., Lawson K.A., Nwokeji E.D., Ma X.
The University of Texas at Austin, Austin, TX, USA
objeCtives: To evaluate utilization patterns and health care costs among chil-
dren in Texas Medicaid diagnosed with otitis media (OM), and analyze the rela-
tionship between index antibiotic medication and prevalence of persistent OM 
(POM). Methods: A retrospective analysis of Texas Medicaid outpatient medical 
and prescription claims from July 2007 to August 2011 for beneficiaries (0-18 years) 
with an OM diagnosis (ICD-9: 381-382) and an associated antibiotic medication was 
conducted. POM was defined as having a subsequent OM diagnosis within 45 days 
after starting the index antibiotic medication. OM-related costs were compared 
across medications and logistic regression was used to evaluate POM likelihood by 
medication with demographics and costs as covariates. Utilization patterns will 
be described graphically using data visualization. Results: The study sample 
included 307,107 patients with a mean age of 3.0 years (SD= 3.8), a majority being 
male (51.9%), Hispanic (63.8%), and from an urban region (84.3%). The overall preva-
lence of POM was 19.3%. Total mean OM episode-related costs were 2.0 times higher 
for POM patients compared to non-POM patients, and the total OM-related cost to 
Medicaid was approximately $58 million. Four index antibiotics (noting their asso-
ciated POM prevalence) were studied: amoxicillin (19.0%), amoxicillin-clavulanate 
(21.2%), azithromycin (15.1%), and cefdinir (21.4%). The second least expensive index 
medication (azithromycin) had the lowest POM prevalence (15.1%) and the second 
lowest mean total OM-related costs ($194; SD= $313). Mean outpatient costs were 
similar between patients taking amoxicillin and cefdinir (the least and most expen-
sive medications, respectively), while amoxicillin-clavulanate and azithromycin 
patients’ outpatient costs were significantly higher (p< 0.01). Age, race, Texas region, 
index medication, and index medication cost category (low vs. high) were significant 
predictors (p< 0.01) of a POM episode. ConClusions: The data suggest different 
POM prevalence among index antibiotic medications, with POM patients accounting 
for a disproportionally higher portion of OM-related health care costs.
SenSory SyStemS diSorderS – clinical outcomes Studies
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acetaminoPhen iS aSSociated With SeriouS Skin reactionS
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objeCtives: To detect and clarify signals of serious skin reactions associated with 
acetaminophen, including Stevens-Johnson syndrome (SJS), toxic epidermal necrol-
ysis (TEN), and acute generalized exanthematous pustulosis (AGEP). Methods: 
Cases reported to FDA adverse event reporting system between 1997 and 2012 
were retrieved. The MedDRA Preferred Terms were used to define serious skin 
reactions. Acetaminophen products were identified by generic names. Empirical 
Bayes Geometric Mean (EBGM) with 95% confidence interval (EB05-EB95) was cal-
culated as disproportionality measure. Safety signals with EB05≥ 2 was considered 
a significant disproportional increase in event reporting of at least twice times 
higher than expected. Signals were reported for single-ingredient acetaminophen 
products, acetaminophen-containing combination products. Results: A total of 
1,295 reports of serious skin reactions were submitted for acetaminophen (592) 
and acetaminophen-containing products (703). Strongest serious skin event signals 
were detected for acetaminophen (EBGM= 5.03, EB05-EB95= 4.68-5.40) followed by 
acetaminophen-containing products (EBGM= 2.93, EB05-EB95= 2.75-3.13). Signals of 
SJS (n= 262, EB05= 3.29), TEN (n= 266, EB05= 7.15), and AGEP (n= 64, EB05= 5.55) were 
detected for acetaminophen. Except for SJS (n= 316, EB05= 1.94), signals of TEN 
(n= 304, EB05= 4.00) and AGEP (n= 83, EB05= 3.68) were detected for acetaminophen-
containing products. ConClusions: Treatment with acetaminophen might be 
associated with risks of serious skin reactions, including SJS, TEN, and AGEP. Patients 
should discontinue acetaminophen and seek medical attention when signs and 
symptoms of skin reactions occur. Signal evaluation measures are required to fur-
ther characterize the dermal risk profile of acetaminophen.
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objeCtives: Several cases of acute angle-closure glaucoma (AACG) have been 
reported due to use of inhaled anticholinergics. This study aims to evaluate the 
association between use of inhaled anticholinergics and risk of AACG among a 
population with chronic obstructive pulmonary disease (COPD). Methods: A 
nested case-control study was conducted among a cohort of subjects with new 
use of COPD medications in the IMS Lifelink Health Databases from Jan 1st 2005 to 
Dec 31st2011. Cases were identified as those with a new diagnosis of AACG (ICD-9 
365.22). For each case, up to 4 controls were randomly selected and matched on age, 
gender, geographic area, prevalent glaucoma, and cohort entry year and quarter 
using incident-density sampling. Conditional logistic regression was used to com-
pute the odds ratio (OR) and 95% confidence interval (CI) for active and previous 
use of inhaled anticholinergics. Active use was defined as concurrent use of inhaled 
anticholinergics on the event date. Previous use was defined as patients receiving 
prescription of inhaled anticholinergics one year prior to the event date. Results: 
The study cohort was comprised of 231,256 patients with a COPD diagnosis and 
first-use of COPD medications. The average age was 70.2 years old and 45.6% were 
males. A total of 261 cases with AACG were matched to 1,016 controls. Active use 
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gologic diseases marketed in Japan. Contact dermatitis (CD) is one of well-known 
adverse events provoked by fradiomycin sulfate. The objectives of this study were to 
investigate the incidence of CD after the prescription of topical drugs containing fra-
diomycin in clinical practice and to assess background characteristics of the patients 
who were diagnosed CD by using Japanese health care database (HDB). Methods: 
The data were extracted from Japanese HDB (MinaCare Co. Ltd) which contained 
data from people covered by employment-based insurances as of April 2013. We 
classified the patients into three groups with prescription of F/M, fradiomycin sul-
fate - betamethasone sodium phosphate combination ointment (F/B, comparable 
to F/M) or betamethasone sodium phosphate solution (B, as a negative control), 
respectively. The ICD-10 classification was used to identify CD required medication 
after the prescription. Background characteristics of the patients who were diag-
nosed CD after the prescription was also investigated. Results: Out of 1,223,905 
patients (male: 531,030, female: 692,875), we have identified the F/M group (20,702 
patients), the F/B group (5,540 patients) and the B group (108,810 patients). In the F/M 
group, CD which was suspected causal relationship with the drug was detected in 
around 0.25% of patients according to the chronological order of the prescription and 
diagnosis in claim database. Similar tendency was observed in the F/B group, while 
lower incidence of CD was observed in the B group. ConClusions: We utilized 
MinaCare HDB to assess the incidence of CD required medication after topical drugs 
prescription in real clinical settings. CD was detected at higher incidence with the 
drugs containing fradiomycin than steroid alone. While further analysis is needed 
for more accuracy, our approach designed to diminish limitations’ influences was 
useful to assess risk and benefit of drugs.
SenSory SyStemS diSorderS – cost Studies
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ocriPlaSmin can reduce health care SPending By PreVenting 
Vitrectomy in PatientS With SymPtomatic Vitreomacular adheSion 
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Arnold R.J.G.1, Graham J.1, White K.2
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objeCtives: sVMA is a serious, sight-threatening and progressive condition which, 
if untreated, leads to irreversible retinal damage, vision loss, and reduced visual 
function. Current standard of care for sVMA is vitrectomy, which has a high rate 
of complications and requires patients to maintain a “head-down” position for up 
to two weeks, resulting in additional surgical costs, discomfort and significant car-
egiver burden. Ocriplasmin (Jetrea®), a single intravitreal injection to resolve sVMA, 
was recently approved in the UK and US. A budget impact analysis was performed 
to test the hypothesis that ocriplasmin can provide cost savings to a hypothetical 
managed care plan by reducing total vitrectomies to resolve sVMA. Methods: 
An Excel-based economic model was designed from the perspective of a managed 
care plan to quantify total direct costs of treating patients with sVMA across two 
scenarios: 1) the current treatment paradigm, consisting of clinical management 
or vitrectomy, and 2) future treatment paradigm, which also includes ocriplasmin 
or ocriplasmin followed by vitrectomy. The model assumes costs are all-inclusive 
over a 1-year period and accounts for diagnosis and monitoring, vitrectomy, intra-
vitreal injection procedures, pharmacy, and treatment of complications. Costs were 
obtained from 2012 Medicare fee-for-service rates and Medicare claims using the 
2005-2009 Outpatient and Part B 5% Standard Analytical Files. Results: Based on 
an aggregate market penetration of 23% (replacing 44% of vitrectomy patients and 
2.5% of clinical management patients), ocriplasmin reduces total vitrectomies by 
35%, resulting in cost savings of $27,884 per year to a 1 million-member health plan. 
Major cost impact drivers include cost of vitrectomy and associated complications, 
cost of ocriplasmin and complications, and percent of ocriplasmin patients requir-
ing vitrectomy. ConClusions: In addition to reducing surgical complications and 
improving patient quality of life, ocriplasmin has the potential to reduce direct 
medical costs to a managed care plan for treating sVMA.
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objeCtives: Identify the real world treatment patterns, medical history, resource 
use and costs of patients with choroidal neovascularization (CNV) secondary to 
pathologic myopia (PM), or myopic CNV (mCNV), in Canada. Methods: Ninety-
eight (98) patients with mCNV from 16 centres across Canada were included in this 
retrospective study. Medical records covering at least one year and up to two years 
of follow up data from the CNV diagnosis were analyzed to gather all information 
related to mCNV. Results: Patients had a mean age of 55.0 years (range: 22 - 82 
years) at the time of their first lifetime CNV episode. Baseline characteristics of 
patients showed that 71.4% of participants were female, 57.1% and 28.6% had sub-
foveal or juxtafoveal CNV in the affected eye, respectively. The bilaterality of mCNV 
was 13.3%. The approximate mean Snellen score at the time of CNV diagnosis was 
20/125 in the affected eye and 20/80 in the fellow eye. Forty-nine percent (49%) of 
patients had visual acuity (VA) severity in the affected eye of normal/mild vision 
loss (VA 20/20 to > 20/80), 19% moderate vision loss (VA 20/80 to > 20/200), and 32% 
severe vision loss/nearly blind (VA ≤ 20/200). The mean duration of CNV episode was 
0.78 years. Almost 90% of mCNV patients consulted a Retina Specialist (on average 
6.0 times/year), 11.2% of patients had to visit the ER and 2.0% were admitted to 
hospital due to mCNV. Most patients were treated with an anti-VEGF therapy and 
received on average 3.8 injections per year. The annual average myopic CNV-related 
cost per patient was $3,433. The cost was $2,964, $3,595 and $4,060 for patients with 
mild, moderate and severe vision loss, respectively. ConClusions: This is the first 
this study, 211 patients with mCNV were matched for demographic characteristics 
with 211 PM controls. Results: The prevalence of CNV secondary to PM was esti-
mated to be 0.084% in the general adult population with an annual incidence of 
0.0061%. Amongst PM patients, 6.2% develop CNV. The bilaterality of mCNV was 10%. 
CNV was mostly subfoveal (87%) and was more common in women than men. At the 
time of CNV diagnosis, the mean Snellen score was 20/100 in the affected eye. The 
most common treatments were verteporfin and laser photocoagulation. The burden 
of resource use, including hospitalizations and emergency, general practitioners 
clinic and ophthalmology visits, is more important in mCNV patients than in PM 
patients (p< 0.01). ConClusions: In a Canadian real-world setting, the prevalence 
and the annual incidence of myopic CNV was 0.084% and 0.0061%, respectively. This 
is the first Canadian study investigating the epidemiology of myopic CNV and the 
results will help us better understand this debilitating disease.
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objeCtives: Few data on the epidemiology and costs of vitreomacular traction 
(VMT) in France are available. Therefore, a study was conducted to evaluate the 
management and associated costs of the most severe forms of this condition, 
which are treated by vitrectomy. Methods: A retrospective, observational study 
was conducted using the French hospital discharge database (PMSI) by identify-
ing all patients having undergone a vitrectomy in 2009 for VMT, with or without 
a macular hole. There was a follow-up period of 2 years. Medical records were 
analyzed by health informatics doctors from 4 hospitals in order to establish an 
extraction algorithm for the relevant patient stays, in the absence of formal VMT 
codes. Patient characteristics, length of stay, rehospitalization for an ophthalmic 
reason, and hospital charges were described. Results: In 2009, 3,463 patients 
were hospitalized for a first-time vitrectomy related to VMT. The mean age was 
68.9 years, with 59% being women. The initial length of stay was primarily 2 to 3 
days (respectively for 21% and 55% of patients, mean of 2.8). Approximately 11% 
of patients underwent concomitant cataract surgery. During the 2-year follow-up, 
48.6% of patients were rehospitalized for an ophthalmic reason, mainly for cata-
ract surgery (75.7%) or retinal tear and/or detachment (14.8%), with an average stay 
of 3 days. The mean charge for the initial stay was € 2,697 and the mean charge for 
rehospitalization for ophthalmic reasons was € 2,930 per stay. ConClusions: This 
study is the first providing extensive data on epidemiology and hospital journeys 
for patients suffering from VMT and treated by vitrectomy in France. Our study 
shows that there is a high rate of rehospitalization for ophthalmic causes at 2 
years post-vitrectomy, and the economic impact is sizeable. Early treatment of 
VMT could reduce the need for surgery and the complications of advanced forms 
of this condition.
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objeCtives: Describe the epidemiological characteristics and treatments for 
chronic plaque psoriasis in a large, Canadian, real-world dataset. Methods: This 
was an observational, retrospective cohort of patients ≥ 18 years who, between 
2008 and 2012 received a diagnosis of psoriasis (overall, scalp, nail, chronic 
plaque, pustular, palmoplantar pustulosis and guttate psoriasis) identified 
by ICD9-10 and/or text coding, and who were prescribed at least 1 treatment. 
Data were retrieved from the Southwestern Ontario (SWO) database, which is 
a representative primary care, researchable database of over 325,000 unique 
patient records in Ontario, Canada. Results: Among 325,618 patients in the 
SWO database, 7,935 patients had a diagnosis of psoriasis between January 1, 
2008 and December 31, 2012 (prevalence 2.44%). Of these, 98% (n=7,776) were 
treated. Chronic plaque psoriasis was the most common subtype of psoriasis 
(85%, n=6,610), followed by scalp psoriasis (50%, n=3,888) in patients receiving 
treatment. Among chronic plaque psoriasis patients, duration of disease ranged 
from 1 to 23 years. Mean age at diagnosis was 31 (sd=12) years. Patients with mild 
disease were generally treated with topicals, most commonly corticosteroids 
(65%), salicylic acid (28%) and/or coal tar (19%). Phototherapy (NB-UVB, 
psoralen+UVA) and oral systemic agents (acitretin, cyclosporine, methotrexate) 
were also prescribed. Twenty eight percent (28%) of chronic plaque psoriasis 
patients had a moderate to severe condition. About 60% of moderate to severe 
patients were treated with phototherapy, whereas 33% were prescribed biologics 
(adalimumab, etanercept, infliximab, ustekinumab). ConClusions: Psoriasis 
is a significant problem in primary care, affecting over 2% of the population. 
Of these, 85% have chronic plaque psoriasis and 28% are considered moderate 
to severe. Results of this study confirm those observed in the literature. This 
real-world database may be used as a resource for further examination of the 
effectiveness of psoriasis treatment and health resource use.
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an outcome Study of the incidence of contact dermatitiS 
after the adminiStration of toPical fradiomycin (neomycin) – 
methylPredniSolone By uSing JaPaneSe health care dataBaSe
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objeCtives: Fradiomycin sulfate - methylprednisolone combination ointment (F/M) 
is an anti-inflammatory topical drug indicated for ophthalmologic or otorhinolaryn-
